Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Preclinical AD predicts decline in memory and executive functions in subjective complaints

van Harten, Argonde C., Smits, Lieke L., Teunissen, Charlotte E., Visser, Pieter J., Koene, Teddy, Blankenstein, Marinus A., Scheltens, Philip, van der Flier, Wiesje M. · 2013 · Neurology

Abstract

OBJECTIVE: We assessed whether preclinical Alzheimer disease (AD) based on CSF biomarkers at baseline predicts decline in cognitive functioning as measured by repeated neuropsychological tests for 4 cognitive domains in patients with subjective complaints. METHODS: We included 132 patients with subjective complaints from our memory clinic-based Amsterdam Dementia Cohort, who underwent lumbar puncture and had repeated (range 2-7) neuropsychological evaluations. Follow-up was 2 ± 1 years. CSF biomarkers amyloid-β (Aβ42), total tau (Tau), and hyperphosphorylated tau-181 were used to define National Institute on Aging-Alzheimer's Association (NIA-AA) preclinical AD stages. Predictive value of preclinical AD stages as defined by CSF biomarkers, individual biomarkers, and Aβ42/tau ratio was assessed using linear mixed models. Outcome measures were compound z scores for memory, attention, executive functioning, language, and global cognition. Analyses were adjusted for age, sex, and education. RESULTS: Patients were 61 ± 8 years old; 56 (42%) were women. Average baseline Mini-Mental State Examination score was 28.3 ± 1.5. Patients who fulfilled criteria for preclinical AD (stage 1: n = 11 + stage 2: n = 10) showed decline over time in memory (β ± SE -0.41 ± 0.14, p < 0.01), executive functions (-0.21 ± 0.08, p < 0.01), and global cognition (-0.29 ± 0.10, p < 0.01). There were no differences in cognitive decline between NIA-AA preclinical AD stages 1 and 2. In patients with normal CSF biomarkers, we observed memory improvement (0.19 ± 0.07, p < 0.01) and stable performance in all other domains. CONCLUSIONS: CSF evidence of preclinical AD in patients with subjective complaints predicted cognitive decline over time, encompassing more than memory alone. Executive functioning and global cognitive functioning also deteriorated. On the other hand, 2-year prognosis for patients without evidence of AD pathophysiology was good.

Overview

Integrity signals

Registry

Crossref · 10.1212/wnl.0b013e3182a8418b

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Research works printed but not linked: 4

  1. Rey A. l'Examen Clinique en Psychologie (The Clinical Examination in Psychology), 2nd ed. Paris: Presse Universitaire de France; 1964.
  2. Saan RJ, Deelman BG. De 15-woorden test A en B: Een voorlopige handleiding (intern raport) (in Dutch). Groningen: Afdeling Neuropsychologie AZG; 1986.
  3. Luteijn F, van der Ploeg FAE. GIT: Groninger Intelligentie Test (in Dutch). Lisse: Swets & Zeitlinger; 1982.
  4. Verhage F. Intelligence and Age: Study With Dutch People Aged 12-77 (in Dutch). Assen: Van Gorcum; 1964.

Cited by

See all 158

Metadata

Authors
van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M.
Affiliations
  • From the Alzheimer Center (A.C.v.H., L.L.S., P.J.V., T.K., P.S., W.M.v.d.F.), Department of Neurology (A.C.v.H., L.L.S., P.S., W.M.v.d.F.), Neuroscience Campus Amsterdam (A.C.v.H., L.L.S., C.E.T., P.J.V., P.S., W.M.v.d.F.), Department of Clinical Chemistry (C.E.T., M.A.B.), Department of Medical Psychology (T.K.), and Department of Epidemiology/Biostatistics (W.M.v.d.F.), VU University Medical Center, Amsterdam; and the Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg (P.J.V.),...
  • Maastricht University Medical Centre (NL)
Venue
Neurology
Published
2013-10-15
Volume
81
Issue
16
Pages
1409-1416
ISSN
  • 0028-3878 (ISSN-L)
  • 1526-632X
OpenAlex
W2106869028
Cited by
143
References
36
Citations by year
2026: 3 · 2025: 10 · 2024: 6 · 2023: 6 · 2022: 11 · 2021: 7 · 2020: 10 · 2019: 14 · 2018: 14 · 2017: 17 · 2016: 16 · 2015: 18 · 2014: 11
FWCI
10.67
Type
journal article
Language
en
Open access
closed
Locations
  • Neurology (publishedVersion)
  • PubMed (publishedVersion)
  • Research Publications (Maastricht University) (publishedVersion)
  • Pure Amsterdam UMC (publishedVersion)
  • Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
  • Research Publications (Maastricht University) (submittedVersion)
  • Data Archiving and Networked Services (DANS) (submittedVersion)
Topics
  • Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
  • Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
  • Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords
preclinical Alzheimer's disease, cerebrospinal fluid biomarkers, amyloid-beta 42, total tau, NIA-AA criteria, subjective complaints, cognitive decline, memory decline, executive function, global cognition, prognosis
MeSH terms
Aged, Alzheimer Disease, Cognition Disorders, Female, Humans, Male, Memory Disorders, Middle Aged, Neuropsychological Tests, Predictive Value of Tests, Prognosis, Biomarkers, Amyloid beta-Peptides, tau Proteins, Disease Progression, Executive Function, Prodromal Symptoms

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Preclinical AD predicts decline in memory and executive functions in subjective complaints. https://app.cochat.ai/papers/10.1212/wnl.0b013e3182a8418b
The paper
van Harten, A. C., Smits, L. L., Teunissen, C. E., Visser, P. J., Koene, T., Blankenstein, M. A., Scheltens, P., & van der Flier, W. M. (2013). Preclinical AD predicts decline in memory and executive functions in subjective complaints. Neurology. https://doi.org/10.1212/wnl.0b013e3182a8418b

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.